Stocks and Investing Stocks and Investing
Thu, February 22, 2024

Andrew Fein Reiterated (UTHR) at Strong Buy and Held Target at $300 on, Feb 22nd, 2024


Published on 2024-10-28 09:08:40 - WOPRAI, Andrew Fein
  Print publication without navigation


Andrew Fein of HC Wainwright & Co., Reiterated "United Therapeutics Corporation" (UTHR) at Strong Buy and Held Target at $300 on, Feb 22nd, 2024.

Andrew has made no other calls on UTHR in the last 4 months.



There are 4 other peers that have a rating on UTHR. Out of the 4 peers that are also analyzing UTHR, 1 agrees with Andrew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Chris Shibutani of "Goldman Sachs" Upgraded from Strong Sell to Hold and Increased Target to $215 on, Monday, February 12th, 2024


These are the ratings of the 3 analyists that currently disagree with Andrew


  • Roanna Ruiz of "Leerink Partners" Initiated at Buy and Held Target at $330 on, Monday, February 5th, 2024
  • Terence Flynn of "Morgan Stanley" Maintained at Buy with Decreased Target to $314 on, Thursday, November 2nd, 2023
  • Jessica Fung of "JP Morgan" Maintained at Buy with Increased Target to $294 on, Thursday, November 2nd, 2023
Contributing Sources